Drugs / XMT-1107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01011972 | Mar 2010 → Sep 2013 | metastatic neoplasm | Mersana Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XMT-1107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01011972 ↗ |
| Route | Intravenous | “administered intravenously over 90 minutes every 21 days” NCT01011972 ↗ |